Hims Hers Health Inc logo

Hims Hers Health Inc(HIMS)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$19.73
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for HIMS

11/13/2026: HIMS (1-star) is currently NOT-A-BUY. Pass it for now.

Hims & Hers Health Inc is a high-growth telehealth platform that provides consumers with direct access to medical treatments for various lifestyle conditions. Its business strength lies in a strong brand, a scalable subscription model, and the ability to offer personalized treatments through internal compounding. The company's primary growth opportunity centers on expanding its footprint in high-demand areas like weight loss and mental health. However, investors face risks, including potential regulatory changes in telehealth prescribing and intense competition from established health retailers. The stock may best suit growth investors comfortable with volatility, while stakeholders should closely monitor regulatory news and subscriber retention metrics.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company exhibits rapid revenue expansion and aggressive market penetration in high-demand health categories.
Momentum investorStrong fit while signal remains positiveStrong revenue growth and shifting sentiment around weight-loss offerings make this a potential target for momentum-based strategies.
Value investorWeak fitThe company is valued primarily on future growth prospects rather than current cash flow or asset value.
Dividend investorWeak fitThe company reinvests all available capital into growth and does not pay a dividend.
Low-risk investorWeak fitHigh volatility and regulatory uncertainties make this stock unsuitable for conservative, risk-averse portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighGrowth-stage stocks often experience wide price swings based on sentiment and quarterly subscriber data.
Valuation riskMedium / highFuture growth expectations are already reflected in the premium valuation.
Competition risk (Direct Telehealth)HighThe sector is crowded with well-capitalized incumbents and low-barrier-to-entry digital health startups.
Business qualityMediumThe company has a strong brand, but it remains dependent on marketing spend and variable regulatory environments.
Dividend incomeLow / noneThe business model is currently optimized for growth rather than capital returns.
Execution riskMedium / highSuccess depends on continuously acquiring subscribers while maintaining low churn and managing clinical complexity.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 4.62B USD
Price to earnings Ratio -
1Y Target Price 28.31
Price to earnings Ratio -
1Y Target Price 28.31
Volume (30-day avg) 13.8M shares
Beta 2.5
52 Weeks Range 13.74 - 40.99
Updated Date 11/14/2026
52 Weeks Range 13.74 - 40.99
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.83

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
66.7%
Active BUY / eligible
8 / 12
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 79.98%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
Stock Returns Performance Upturn Returns Performance icon 4.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
HIMS receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by soft unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
HIMS has solid overall fundamentals (4 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, moderate earnings growth (+1.8%) and strong revenue growth (+59.0%) are partially offset by soft cash generation (FCF margin 3.2%), soft profitability (net margin 5.5%).

Financial Health Rating

★★★★★
HIMS's financial health is supported by solid cash strength, including free-cash-flow generation (3.2% of revenue). Profitability is moderate (3 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is HIMS's strongest growth driver at +59.0% FY2025 versus FY2024 (strong, 5 stars). By comparison, while earnings growth (+1.8%, moderate) and free-cash-flow growth (-62.7%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 68.1% and approximately 95.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 6.95% supports management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 12.30%
Vanguard Portfolio Management, LLC 4.53%
Vanguard Capital Management, LLC 4.09%
State Street Corp 3.49%
Morgan Stanley - Brokerage Accounts 3.07%

Unit Economics (Per $1K Revenue)

★★★★★
HIMS generates approximately $738 of gross profit, $45 of operating income, and $32 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Moderate margins explain the 2-star rating, with weak cash conversion and moderate capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -3.58% (Tax Credit)

Quantitative Style Profile

★★★★★
HIMS has a liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Subscription ServicesRecurring revenue from prescribed medications and wellness product shipments.Most of the company's money comes from loyal customers who subscribe to ongoing health plans.
Consultation FeesFees charged for virtual visits with independent medical providers.Small portion of revenue generated by the platform acting as a bridge between patients and doctors.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-09
When After Market
Estimate 0.07
Actual 0.03

Profitability

Profit Margin -6.65%
Operating Margin (TTM) -6.39%

Management Effectiveness

Return on Assets (TTM) -3.96%
Return on Equity (TTM) -40.77%

Valuation

Trailing PE -
Forward PE 51.28
Enterprise Value 5.47B
Price to Sales(TTM) 1.61
Enterprise Value 5.47B
Price to Sales(TTM) 1.61
Enterprise Value to Revenue 1.91
Enterprise Value to EBITDA 205.86
Shares Outstanding 226.03M
Shares Floating 214.85M
Shares Outstanding 226.03M
Shares Floating 214.85M
Percent Insiders 6.95
Percent Institutions 68.12

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.